Immucell Stock – Fundamental Analysis

Price
10.75
10/14/2026
Oct 1996
Oct 2026

Fundamental Data & Ratios (Balance sheet update: 4/3/2026)

Balance Sheet Total Assets 42,532,000.00 ROE 63.61 %
Balance Sheet Total Equity 27,055,500.00 ROA -2.45 %
Cashflow Capital Expenditures -1,250,440.00 P/FCF 79.22
Cashflow Free Cash Flow 1,224,850.00 – –
Cashflow Operating Cash Flow 2,475,290.00 P/CF 39.20
Income Earnings per Share (diluted) -0.12 Div. Yield –
Income Net Income -1,040,000.00 P/E -89.58
Income Shares Outstanding 9,026,000.00 P/B 3.59
Income Total Revenue 27,644,000.00 P/S 3.51

Ratios calculated on: 10/14/2026

Company Description

ImmuCell Corporation creates scientifically proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. The Company´s product, First Defense, is manufactured from cows´ colostrum using the Company´s vaccine and whey protein purification technologies. The target disease, bovine enteritis (calf scours), causes diarrhea and dehydration in newborn calves and often leads to serious sickness and even death. First Defense is the only USDA-licensed, orally delivered scours preventive product on the market for calves with claims against E. coli K99 and coronavirus (two causes of scours). First Defense provides bovine antibodies that newborn calves need. Wipe Out Dairy Wipes consist of biodegradable towelettes that are pre-moistened with a Nisin to prepare the teat area of a cow in advance of milking.

Advanced Analysis Features

Additional comparison and history views are available after login.

Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.immucell.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown. Learn more